Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets.
The company has invested heavily in research and development and marketing for two drugs in particular, donanemab for treatment of Alzheimer's disease and tirzepatide for obesity. They are planning on releasing data from testing phases soon and gaining approval for donanemab early in 2023.
The company’s shares have been up this past year, by 31%, although they have predicted a lower profit margin in 2023 due to higher spending and share prices falling by 1%.
Tirzepatide, under the brand name Mounjaro, gained approval from the US regulators in 2022 for use in treating type 2 diabetes to be administered as a once-weekly subcutaneous injection.
Eli Lilly are anticipating costs associated with the drug’s marketing and other expenses to hit in the region of $6.9 billion to $7.1 billion, $500 million more than in 2022.
"I think we see two of them as kind of generational opportunities, tirzepatide for obesity and donanemab, and the other three as being great opportunities in very competitive spaces," Lilly Chief Executive David Ricks stated.
The other drugs in the portfolio to be released next year are mirikizumab for inflammatory bowel disease, lebrikizumab for atopic dermatitis, and pirtobrutinib for the treatment of multiple B-cell malignancies.
Lilly is also projecting a spend of $8.2 billion to $8.4 billion on their research and development programmes.
Refinitiv, the financial market data and infrastructure provider, is predicting that these large-scale investments will pay off, projecting revenue of between $30.3 billion and $30.8 billion in 2023 for Eli Lilly.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance